Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
16.60
-0.30 (-1.78%)
At close: Jun 27, 2025, 4:00 PM
18.21
+1.61 (9.70%)
After-hours: Jun 27, 2025, 5:17 PM EDT
Crescent Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | 0.01 | 0.08 | 1.16 | 10.16 | |
| Revenue Growth (YoY) | - | - | -86.67% | -93.53% | -88.59% | - | |
| Gross Profit | - | - | 0.01 | 0.08 | 1.16 | 10.16 | |
| Selling, General & Admin | 15.54 | 18.25 | 19.21 | 19.09 | 17.12 | 16.74 | |
| Research & Development | 8.25 | 14.26 | 20.07 | 28.39 | 47.49 | 44.93 | |
| Operating Expenses | 23.79 | 32.51 | 39.29 | 47.48 | 64.61 | 61.67 | |
| Operating Income | -23.79 | -32.51 | -39.28 | -47.4 | -63.45 | -51.51 | |
| Interest & Investment Income | 0.61 | 0.94 | 2.38 | 0.71 | 0.02 | 0.48 | |
| EBT Excluding Unusual Items | -23.18 | -31.57 | -36.9 | -46.69 | -63.43 | -51.03 | |
| Merger & Restructuring Charges | -7.53 | -7.53 | - | - | - | - | |
| Gain (Loss) on Sale of Assets | 1.22 | 1.22 | - | - | - | - | |
| Pretax Income | -29.49 | -37.88 | -36.9 | -46.69 | -63.43 | -51.03 | |
| Net Income | -29.49 | -37.88 | -36.9 | -46.69 | -63.43 | -51.03 | |
| Net Income to Common | -29.49 | -37.88 | -36.9 | -46.69 | -63.43 | -51.03 | |
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 1 | 0 | |
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 1 | 0 | |
| Shares Change (YoY) | 0.19% | 1.79% | 20.58% | 2.10% | 12.54% | 5.70% | |
| EPS (Basic) | -45.72 | -58.75 | -58.25 | -88.88 | -123.27 | -111.60 | |
| EPS (Diluted) | -45.72 | -58.75 | -58.25 | -88.88 | -123.27 | -112.00 | |
| Free Cash Flow | -25.7 | -31.11 | -34.9 | -46.54 | -57.5 | -39.31 | |
| Free Cash Flow Per Share | -39.85 | -48.25 | -55.10 | -88.60 | -111.76 | -85.98 | |
| Gross Margin | - | - | 100.00% | 100.00% | 100.00% | 100.00% | |
| Operating Margin | - | - | -392752.93% | -63204.43% | -5470.69% | -506.84% | |
| Profit Margin | - | - | -368994.20% | -62251.74% | -5468.98% | -502.09% | |
| Free Cash Flow Margin | - | - | -349012.97% | -62055.57% | -4958.28% | -386.80% | |
| EBITDA | -23.76 | -32.47 | -39.12 | -47.2 | -63.18 | -51.24 | |
| D&A For EBITDA | 0.03 | 0.04 | 0.15 | 0.21 | 0.26 | 0.27 | |
| EBIT | -23.79 | -32.51 | -39.28 | -47.4 | -63.45 | -51.51 | |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.